Ligand Announces Closing of Convertible Senior Notes Offering
Rhea-AI Summary
Ligand (Nasdaq: LGND) closed a 0.00% convertible senior notes offering due 2031 with an aggregate principal amount of $700 million, including $75 million from the option exercise.
Net proceeds were about $678.2 million, allocated to note hedges, a share repurchase, and general corporate purposes.
Positive
- Raised $700 million principal of 0.00% convertible senior notes due 2031
- Net cash proceeds of approximately $678.2 million after fees and expenses
- About $60 million used to repurchase 228,859 shares at $262.17 per share
- Approximately $72.9 million allocated to convertible note hedge transactions
- Convertible note hedges expected to reduce dilution and excess cash payments on conversion
Negative
- Warrant transactions may dilute equity if share price exceeds $524.34 strike price
- Convertible structure introduces potential future dilution to common shareholders
News Market Reaction – LGND
In the Jun 26 session, LGND gained 2.59%, reflecting a moderate positive market reaction. Argus tracked a trough of -4.9% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 23 | Convertible notes pricing | Neutral | +6.6% | Priced upsized $625M 0.0% 2031 convertible notes plus additional $75M option. |
| Jun 22 | Proposed notes offering | Neutral | -4.6% | Proposed $550M 2031 convertible notes with $82.5M option and hedge, warrant plans. |
| Aug 14 | Notes offering closing | Neutral | -1.8% | Closed $460M 0.75% 2030 convertible notes with hedge and warrant transactions. |
| Aug 11 | Notes pricing 2030 | Neutral | +3.9% | Priced $400M 0.75% 2030 convertible notes with 32.5% conversion premium. |
| Aug 11 | Proposed 2030 notes | Neutral | -2.0% | Proposed $400M 2030 convertible notes plus $60M option and related hedges. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Offering-related announcements for LGND have produced mixed, generally modest share reactions, with both positive and negative moves around similar financing events.
Key Terms
convertible senior notes financial
convertible note hedge transactions financial
warrant transactions financial
strike price financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Opportunistic capital raise with proceeds used to enhance financial flexibility
- A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution to Ligand’s common stock upon conversion of the notes
JUPITER, Fla., June 25, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today that it completed its previously announced offering (the “offering”) of
Use of Proceeds
The net proceeds from the offering were approximately
Convertible Note Hedge Transactions
In connection with the pricing of the notes and the initial purchasers’ exercise of their option to purchase additional notes, Ligand entered into convertible note hedge transactions (the “convertible note hedge transactions”) with certain of the initial purchasers or their affiliates and certain other financial institutions (the “option counterparties”). Ligand also entered into warrant transactions (the “warrant transactions”) with the option counterparties in connection with the pricing of the notes and the initial purchasers’ exercise of their option to purchase additional notes, pursuant to which Ligand issued warrants to purchase Common Stock (the “warrants”) to such option counterparties. The convertible note hedge transactions are expected generally to reduce the potential dilution to Ligand’s common stock upon any conversion of notes and/or offset any cash payments Ligand is required to make in excess of the principal amount of converted notes, as the case may be. However, the warrant transactions could separately have a dilutive effect on Ligand’s common stock to the extent that the market price per share of Ligand’s common stock exceeds the strike price of the warrants. The strike price of the warrants will initially be
This press release is neither an offer to sell nor a solicitation of an offer to buy any securities, nor shall it constitute an offer to sell, solicitation of an offer to buy or sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
Forward-Looking Statements
This press release contains “forward-looking” statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “predict,” “intend,” “may,” “might,” “plan,” “project,” “potential,” “seek,” “should,” “target,” “will,” “would” and similar expressions or variations intended to identify forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements concerning the anticipated use of the net proceeds of the offering, the warrant transactions and the additional warrant transactions and the potential impact of the foregoing or related transactions on dilution to holders of Ligand’s common stock, and the market price of Ligand’s common stock and/or the notes are forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various risk factors that are described more fully in Ligand’s reports and other documents filed with the Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2025 and other flings that Ligand makes from time to time with the SEC, which are available on the SEC’s website at www.sec.gov, and could cause actual results to vary from expectations. All information provided in this press release is as of the date hereof, and Ligand undertakes no duty to update or revise this information, whether as a result of new information, new developments or otherwise, except as required by law. These statements are not guarantees of future performance but are based on management’s expectations as of the date of this press release and assumptions that are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements.
About Ligand
Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 100 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network.
Contacts
Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761
Media:
Kellie Walsh
media@ligand.com
(914) 315-6072
